Your session is about to expire
← Back to Search
Radiopharmaceutical
131I-MIP-1095 for Prostate Cancer
Phase 1
Waitlist Available
Led By Michael Morris, MD
Research Sponsored by Memorial Sloan Kettering Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights
Summary
The main purpose of this study to determine the safety of an experimental medicine called 131I-MIP-1095. 131I-MIP-1095 is an investigational drug, meaning it has not been approved by the U.S. Food & Drug Administration (FDA).
Eligible Conditions
- Prostate Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 2 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Maximum Tolerated Dose (MTD)
Trial Design
1Treatment groups
Experimental Treatment
Group I: 131I-MIP-1095Experimental Treatment1 Intervention
FirstTherapeutic Dose with 131I-MIP-1095 to be administered no later than 30 days after dosimetry dose, which will be designated Day 1 of the Treatment Phase 2nd and 3rd Therapeutic Doses with 131I-MIP-1095 to be administered 12 weeks apart Monthly Follow-Up Visits until Week 41. 1st Therapeutic Dose with 131I-MIP-1095 to start after qualifying from dosimetry on Day 8 or no later than 30 days after dosimetry dose.
2nd and 3rd Therapeutic Doses with 131I-MIP-1095 to be administered 12 weeks apart Monthly Follow-Up Visits until Week 53
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
MIP-1095 I-131
Not yet FDA approved
Find a Location
Who is running the clinical trial?
Progenics Pharmaceuticals, Inc.Industry Sponsor
33 Previous Clinical Trials
4,348 Total Patients Enrolled
17 Trials studying Prostate Cancer
1,782 Patients Enrolled for Prostate Cancer
Memorial Sloan Kettering Cancer CenterLead Sponsor
1,944 Previous Clinical Trials
589,741 Total Patients Enrolled
133 Trials studying Prostate Cancer
51,580 Patients Enrolled for Prostate Cancer
Michael Morris, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
15 Previous Clinical Trials
2,859 Total Patients Enrolled
11 Trials studying Prostate Cancer
930 Patients Enrolled for Prostate Cancer
Share this study with friends
Copy Link
Messenger